DIAGNOSIS, STAGING, AND RESPONSE CRITERIA
There is considerable need to evaluate the diagnosis, staging, and response criteria prospectively in clinical trials and retrospectively using existing databases. It is highly likely that refinements will be needed, because such criteria should always be considered a ''work in progress,'' as clinical practice and treatments evolve over time. Challenges to completion of validation studies include the large number of patients from multiple centers required for an adequate statistical evaluation, the protracted time frame needed for adequate observation, and funding needed to support the effort. Jagasia et al. [7] and Arora et al. [8] have recently completed the first single-site retrospective validation studies of the diagnosis and staging criteria. These studies showed a correlation of GVHD subtype (late acute versus classic chronic) and severity with overall survival (OS). At the workshop, Jacobsohn et al [9] presented a comparison of the Johns Hopkins Hospital skin response criteria as used in the recently published pentostatin trial with the NIH consensus response criteria. Their data showed that the 2 scales had similar and complementary, although not identical, properties. Mitchell et al. [10] have performed a small assessment of feasibility and reproducibility of the NIH response criteria in a prospective study conducted at multiple sites in the United States. A large prospective cohort investigation has recently received NIH funding and is led by S. Lee of the Fred Hutchinson Cancer Research Center (FHCRC). A validation project is currently underway led by D. Wolff and the German/European Union (EU) collaborative group [11] .
ORGAN-SPECIFIC RESEARCH AND ANCILLARY AND SUPPORTIVE CARE
Because the multiple-organ clinical manifestations of cGVHD can persist for prolonged periods of time, supportive care is critical in long-term management. Because there is a profound lack of data in these areas, most of the NIH consensus recommendations are based on extrapolation of clinical results from other fields of medicine. To conduct trials in this area it will be essential to develop organ-specific severity scales, which will require long-term data. Research addressing organ dysfunction includes skin, pulmonary, and oral mucosal complications and conjunctival therapeutic intervention studies. The bronchiolitis obliterans syndrome (BOS) is a rare, but devastating, complication in need of improved diagnostic criteria and therapy [12] . Studies of oral mucosa suggest that immunologic features of cGVHD might be quantified by immunohistochemistry. This type of research represents an opportunity to study the immunologic processes of cGVHD directly at the anatomic site of the disease [13] .
BIOLOGY, BIOMARKERS, AND NEW TARGETS
Chronic GVHD is remarkable for lack of insight into the basic biology of the disease. Because of this, there are no validated biomarkers. Targeted drug therapy has been impaired by this absence of specific immunologic targets. Preclinical mouse models that approximate the full spectrum of human cGVHD are lacking, although there are several useful models that demonstrate selected aspects of the disease process (reviewed by Shlomchik et al. [14] and Chu and Gress [15] ). The long duration of follow-up required to assess murine cGVHD has inhibited both the development and utilization of these models. Prior studies using patient samples have focused mainly on peripheral blood, which likely misses mechanisms that function within tissues affected by cGVHD. Studies to characterize new biomarkers and confirm or refute those suggested by smaller studies in cGVHD will require large numbers of samples linked to detailed information on the clinical course. Small studies have suggested a role for diverse immunologic cells/soluble factors including T cells and T cell subsets, thymic-dependent and -independent pathways of T cell recovery, B cells, and B cell subsets, and B cell activating factor (BAFF) [16] [17] [18] [19] . For example, 4 inflammatory plasma markers and an activated B cell population identified as potential biomarkers in cGVHD in a study performed by the Children's Oncology Group (COG) will require validation in a larger population that includes adults [16, 17] . Larger cooperative studies, in particular those conducted by the EU, have included examination of gene polymorphisms in cGVHD [20, 21] , and proteomics studies [22] .
GRAFT-VERSUS-LEUKEMIA (GVL) EFFECTS
Growing clinical evidence suggests a major contribution of cGVHD in mediating allogeneic GVL effects. Research in this important area is lacking, and efforts to investigate the pathophysiologic basis of the GVL effect compared to the GVHD effect should be pursued. Representative presentations at the workshop addressed preclinical models and their limitations, T cell and B cell aspects of the GVL effect, and the role of hematopoietic chimerism. The possibility of a humoral component in the GVL effect, in addition to the documented T cell contribution, was discussed [23] [24] [25] [26] [27] . The relation of cGVHD biomarkers to the GVL effect will be investigated in the COG study of GVHD prophylaxis for children receiving allogeneic HCT for acute lymphoblastic leukemia (see also #NCT00382109 at www.ClinicalTrials.gov).
THERAPEUTIC CLINICAL TRIALS
Regarding design of clinical trials in cGVHD in general, the selection of short-term endpoints was emphasized as key, including consideration of composite endpoints. Challenges to endpoint design include lack of validated short-term predictors (\6 months) of the more long-term outcomes (years) of the natural history of cGVHD, as well as the obvious need for validation studies of response criteria in cGVHD. The trajectory of disease progression should be given more attention when patients are enrolled in a clinical trial. For example, stabilization of disease manifestations could be considered a benefit in a patient with rapidly progressive cGVHD manifestations but not in those with improving or stable manifestations before an intervention. Biologic markers that could be used as short-term predictors of therapeutic benefit would be especially helpful for early drug development trials in cGVHD. Results from recent relatively small phase II studies suggestive of benefit from extracorporeal photopheresis (ECP) and Rituximab (humanized anti-CD20) for the treatment cGVHD were presented [28, 29] . Multicenter studies of mycophenolate mofetil (MMF) and its enteric coated formulation as an adjunct to standard front line cGVHD therapy are currently underway in the United States led by P. Martin at FHCRC (see also #NCT00089141 at www.ClinicalTrials.gov) and in Europe led by G. Socie (#NCT00298324 at www.ClinicalTrials.gov), respectively.
RESOURCES-TRANSPLANT NETWORKS AND CLINICAL TRIALS CONSORTIA
The total number of patients with cGVHD is small, so that cGVHD qualifies as a ''rare disease,'' even though as many as half of all patients undergoing allogeneic HSCT experience this complication. Cooperative clinical studies in cGVHD will be needed to accomplish progress in the field. There is a corresponding need to identify the type of infrastructure that will best facilitate such multicenter projects. Both national and international clinical collaborations should be strongly encouraged. In the United States, 1 or more existing networks, for example, the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), may be well positioned to provide the type of infrastructure needed. In the recent ''BMT CTN State of the Science Symposium'' [30], cGVHD was identified as an area of immediate need for both intensive studies of disease mechanisms as well as therapeutic clinical trials. A proposal for a prospective multicenter clinical trial in cGVHD that would be coupled with immunologic ancillary studies is currently in development by the consortium. The Pediatric Blood and Marrow Transplant Consortium (PBMTC), which is a member of the BMT CTN, is an important resource for study of aspects of cGVHD. The database of the Center for International Blood and Marrow Transplant Research (CIBMTR), which contains information on over 240,000 HCT procedures performed worldwide, serves as a unique and perhaps insufficiently utilized resource available for retrospective analyses in HCT including cGVHD. Practical aspects of International collaborations were discussed at the workshop by representatives of the European Group for Blood and Marrow Transplantation (EBMT), the BMT CTN, and the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP).
RESOURCES-INVESTIGATOR INITIATED RESEARCH
Availability of funding support for studies in cGVHD has been extremely limited. The standard NIH Research Project (R01) format may not be a good fit for applications in cGVHD that need a multicenter or interdisciplinary clinical trials design. For cGVHD in particular, the relatively small number of cases, with lack of clear assignment of responsibility to a single NIH Institute/Center (IC) presents an additional challenge in applying for and successfully obtaining NIH funding. However, even in this era of relative fiscal constraint for the NIH, using the National Institute of Allergy and Infectious Diseases (NIAID) as an example, over half of the annual budget of the Division of Allergy, Immunology and Transplantation (DAIT) remains available for investigator-initiated research, representing a significant opportunity [31] . It may be reasonable to consider cooperation of NIH ICs having a direct or partial interest in cGVHD studies, or support through existing networks or other consortia, when developing a funding plan for large cooperative clinical trials. A Program Project (P01) approach may be appropriate. Interactive discussions with U.S. Government funding agencies should be pursued, to promote intramural and extramural NIH and government-wide collaborations where feasible. Investigators should approach NIH ICs with their proposals for joint ventures. It is likely that the NIH would view collaborative efforts that result in elimination of redundant funding or cost saving as advantageous. Opportunities for funding other than NIH should be considered, including other U.S. Government agencies, such as, for example, the Food and Drug Administration (FDA) Office of Orphan Products Development, as well as private foundations such as the Biomarkers Consortium of the Foundation for the NIH, and others.
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